MediWound (MDWD) Misses Q4 EPS by 3c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
MediWound Reports Fourth Quarter and Full-Year 2019 Financial Results
February 25, 2020 7:01 AM ESTGenerated total full-year 2019 revenues of $31.8 million, driven primarily by Vericel license payment and development services to BARDA
Initiated U.S. Phase 2 adaptive design study of EscharEx for the treatment of venous leg ulcers
BARDA initiated the procurement of NexoBrid valued at $16.5 million for emergency response
Conference call begins today at 8:30 a.m. Eastern Time
YAVNE, Israel, Feb. 25, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical... More
